therapeuticЮжно-Российский журнал терапевтической практикиSouth Russian Journal of Therapeutic Practice2712-81563033-8344РостГМУ10.21886/2712-8156-2022-3-2-7-18therapeutic-247Research ArticleОБЗОРЫREVIEWSВлияние метаболических нару шений на формирование патологии почекInfluence of metabolic disorders on the development of renal pathologyhttps://orcid.org/0000-0001-9344-1304БашкиновР. А.BashkinovR. A.

Башкинов Роман Андреевич, Медицинский советник «Евразийской Ассоциации Терапевтов», Москва; аспирант кафедры терапии, ревматологии, экспертизы временной нетрудоспособности и качества медицинской помощи им. Э. Э. Эйхвальда ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова», Санкт-Петербург

Roman A. Bashkinov, Medical advisor of the «Eurasian Association of Therapists», Moscow; postgraduate of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care n. a. E. E. Eichwald, «North-Western State Medical University n. a. I. I. Mechnikov», Saint-Petersburg

bashkinov-roman@mail.ruhttps://orcid.org/0000-0002-0210-2321БатлукТ. И.BatlukT. I.

Батлук Татьяна Ивановна, к.м.н., ассистент кафедры пропедевтики внутренних болезней педиатрического факультета ФГАОУ ВО «РНИМУ им. Н. И. Пирогова» Минздрава России; медицинский советник «Евразийской Ассоциации Терапевтов»

Москва

Tatiana I. Batluk, PhD, Assistant of Department of Internal Medicine Propaedeutics of the Pediatric Faculty, «Pirogov Russian National Research Medical University»; medical advisor of the «Eurasian Association of Therapists»

Moscow

tatianabatluk92@gmail.comhttps://orcid.org/0000-0002-8521-6542МельниковЕ. С.MelnikovE. S.

Мельников Евгений Сергеевич, медицинский советник «Евразийской Ассоциации Терапевтов», Москва; аспирант кафедры терапии, ревматологии, экспертизы временной нетрудоспособности и качества медицинской помощи им. Э. Э. Эйхвальда ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова», Санкт-Петербург

Evgeny S. Melnikov, Medical advisor of the «Eurasian Association of Therapists», Moscow; postgraduate of the Department of therapy, rheumatology, examination of temporary disability and quality of medical care n. a. E. E. Eichwald, «North-Western State Medical University n. a. I. I. Mechnikov», Saint-Petersburg

melnikovzhenya@mail.ruhttps://orcid.org/0000-0003-4116-096XТрубниковаМ. А.TrubnikovaM. A.

Трубникова Марина Александровна, медицинский советник «Евразийской Ассоциации Терапевтов», Москва; врач-нефролог ООО «Фрезениус Медиал Кеа Кубань», Сочи

Marina A. Trubnikova, Medical advisor of the «Eurasian Association of Therapists», Moscow; nephrologist of LLC «Fresenius Medical Care Kuban», Sochi

mtrubnikova@euat.ruhttps://orcid.org/0000-0003-1180-3549АрутюновА. Г.ArutyunovA. G.

Арутюнов Александр Григорьевич, д.м.н., вице-президент

Москва

Alexander G. Arutyunov, MD, Vice President

Moscow

agarutyunov@mail.ru«Евразийская Ассоциация Терапевтов»; ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Минздрава РоссииРоссия«Eurasian Association of Therapists»; «North-Western State Medical University n. a. I. I. Mechnikov»Russian Federation«Евразийская Ассоциация Терапевтов»; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава РоссииРоссия«Eurasian Association of Therapists»; «Pirogov Russian National Research Medical University»Russian Federation«Евразийская Ассоциация Терапевтов»; ООО «Фрезениус Медиал Кеа Кубань»Россия«Eurasian Association of Therapists»; LLC «Fresenius Medical Care Kuban»Russian Federation«Евразийская Ассоциация Терапевтов»Россия«Eurasian Association of Therapists»Russian Federation20221806202232718Copyright © Башкинов Р.А., Батлук Т.И., Мельников Е.С., Трубникова М.А., Арутюнов А.Г., 20222022Башкинов Р.А., Батлук Т.И., Мельников Е.С., Трубникова М.А., Арутюнов А.Г.Bashkinov R.A., Batluk T.I., Melnikov E.S., Trubnikova M.A., Arutyunov A.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.therapeutic-j.ru/jour/article/view/247

Большой вклад в развитие патологии почек, в том числе и в прогрессирование хронической болезни почек, вносят факторы риска, связанные с нарушением метаболических процессов. К ним относятся нарушения углеводного обмена (предиабет, сахарный диабет), дислипидемии, избыточная масса тела, ожирение, метаболический синдром, гиперурикемия. Своевременное выявление этих факторов и их коррекция могут иметь решающее значения для пациента в контексте почечного повреждения. В обзоре представлены данные о влиянии нарушений углеводного, липидного и пуринового обменов, избыточной массы тела и ожирения на формирование патологии почек.

A large contribution to the development of kidney pathology, including the progression of chronic kidney disease, is made by risk factors associated, among other things, with impaired metabolic processes. These include disorders of carbohydrate metabolism (prediabetes, diabetes mellitus), dyslipidemia, overweight, obesity, metabolic syndrome, hyperuricemia. Timely identification of these factors and their correction can be crucial for the patient in the context of kidney damage. The review presents data on the impact of disorders of carbohydrate, lipid and purine metabolism, overweight and obesity on the formation of kidney pathology.

хроническая болезнь почекизбыточная масса телагиперурикемиядислипидемияпредиабетсахарный диабетchronic kidney diseaseoverweighthyperuricemiadyslipidemiaprediabetesdiabetes mellitusReferencesКлинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82.Клинические рекомендации. Хроническая болезнь почек (ХБП). Нефрология. 2021;25(5):10-82.Tsai WC, Wu HY, Peng YS, Ko MJ, Wu MS, Hung KY, et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore). 2016;95(11):e3013. DOI: 10.1097/MD.0000000000003013.Tsai WC, Wu HY, Peng YS, Ko MJ, Wu MS, Hung KY, et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore). 2016;95(11):e3013. DOI: 10.1097/MD.0000000000003013.Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55(1):66-76. DOI: 10.1007/s12020-016-1014-6.Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55(1):66-76. DOI: 10.1007/s12020-016-1014-6.Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301. DOI: 10.1136/bmj.k5301.Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301. DOI: 10.1136/bmj.k5301.Piani F, Johnson RJ. Does gouty nephropathy exist, and is it more common than we think? Kidney Int. 2021;99(1):31-33. DOI: 10.1016/j.kint.2020.10.015.Piani F, Johnson RJ. Does gouty nephropathy exist, and is it more common than we think? Kidney Int. 2021;99(1):31-33. DOI: 10.1016/j.kint.2020.10.015.Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г., Беленков Ю.Н., Конради А.О., Лопатин Ю.М., и др. Клинические особенности постковидного периода. Результаты международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 АКТИВ SARSCoV-2)». Предварительные данные (6 месяцев наблюдения). Российский кардиологический журнал. 2021;26(10):4708. DOI: 10.15829/1560-4071-2021-4708Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г., Беленков Ю.Н., Конради А.О., Лопатин Ю.М., и др. Клинические особенности постковидного периода. Результаты международного регистра «Анализ динамики коморбидных заболеваний у пациентов, перенесших инфицирование SARS-CoV-2 АКТИВ SARSCoV-2)». Предварительные данные (6 месяцев наблюдения). Российский кардиологический журнал. 2021;26(10):4708. DOI: 10.15829/1560-4071-2021-4708Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г., Беленков Ю.Н., Конради А.О., Лопатин Ю.М. и др. Регистр «Анализ динамики Коморбидных заболеваний у пациенТов, перенесшИх инфицироВание SARS-CoV-2» (АКТИВ). Оценка влияния комбинаций исходных сопутствующих заболеваний у пациентов с COVID-19 на прогноз. Терапевтический архив 2022;94(1):32-47. DOI: 10.26442/00403660.2022.01.201320Арутюнов Г.П., Тарловская Е.И., Арутюнов А.Г., Беленков Ю.Н., Конради А.О., Лопатин Ю.М. и др. Регистр «Анализ динамики Коморбидных заболеваний у пациенТов, перенесшИх инфицироВание SARS-CoV-2» (АКТИВ). Оценка влияния комбинаций исходных сопутствующих заболеваний у пациентов с COVID-19 на прогноз. Терапевтический архив 2022;94(1):32-47. DOI: 10.26442/00403660.2022.01.201320Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784. DOI: 10.1002/14651858.CD007784.pub2.Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014;(5):CD007784. DOI: 10.1002/14651858.CD007784.pub2.Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):251-62. DOI: 10.7326/0003-4819-157-4-201208210-00005.Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157(4):251-62. DOI: 10.7326/0003-4819-157-4-201208210-00005.Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172(10):761-9. DOI: 10.1001/archinternmed.2011.2230. Erratum in: Arch Intern Med. 2012;172(14):1095.Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med. 2012;172(10):761-9. DOI: 10.1001/archinternmed.2011.2230. Erratum in: Arch Intern Med. 2012;172(14):1095.Alizadeh S, Esmaeili H, Alizadeh M, Daneshzad E, Sharifi L, Radfar H, et al. Metabolic phenotypes of obese, overweight, and normal weight individuals and risk of chronic kidney disease: a systematic review and meta-analysis. Arch Endocrinol Metab. 2019;63(4):427-437. DOI: 10.20945/2359-3997000000149.Alizadeh S, Esmaeili H, Alizadeh M, Daneshzad E, Sharifi L, Radfar H, et al. Metabolic phenotypes of obese, overweight, and normal weight individuals and risk of chronic kidney disease: a systematic review and meta-analysis. Arch Endocrinol Metab. 2019;63(4):427-437. DOI: 10.20945/2359-3997000000149.Schwasinger-Schmidt TE, Elhomsy G, Paull-Forney BG. Impact of a Community-Based Weight Loss Program on Renal Function. Cureus. 2020;12(5):e8101. DOI: 10.7759/cureus.8101Schwasinger-Schmidt TE, Elhomsy G, Paull-Forney BG. Impact of a Community-Based Weight Loss Program on Renal Function. Cureus. 2020;12(5):e8101. DOI: 10.7759/cureus.8101Арутюнов А.Г., Башкинов Р.А., Батлук Т.И., Мельников Е.С., Ермилова А.Н. Острое повреждение почек у пациентов с хронической сердечной недостаточностью. Южно-Российский журнал терапевтической практики. 2021;2(3):6-17. DOI: 10.21886/2712-8156-2021-2-3-6-17Арутюнов А.Г., Башкинов Р.А., Батлук Т.И., Мельников Е.С., Ермилова А.Н. Острое повреждение почек у пациентов с хронической сердечной недостаточностью. Южно-Российский журнал терапевтической практики. 2021;2(3):6-17. DOI: 10.21886/2712-8156-2021-2-3-6-17Plantinga LC, Crews DC, Coresh J, Miller ER3rd, Saran R, Yee J, et al.; CDC CKD Surveillance Team. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673-82. DOI: 10.2215/CJN.07891109.Plantinga LC, Crews DC, Coresh J, Miller ER3rd, Saran R, Yee J, et al.; CDC CKD Surveillance Team. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5(4):673-82. DOI: 10.2215/CJN.07891109.Evron JM, Herman WH, McEwen LN. Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c Testing. Diabetes Care 2019;42:576-584. Diabetes Care. 2020;43(9):2323. DOI:10.2337/dc20-er09.Evron JM, Herman WH, McEwen LN. Changes in Screening Practices for Prediabetes and Diabetes Since the Recommendation for Hemoglobin A1c Testing. Diabetes Care 2019;42:576-584. Diabetes Care. 2020;43(9):2323. DOI:10.2337/dc20-er09.Forouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med. 2007;24(2):200-207. DOI: 10.1111/j.1464-5491.2007.02068.xForouhi NG, Luan J, Hennings S, Wareham NJ. Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med. 2007;24(2):200-207. DOI: 10.1111/j.1464-5491.2007.02068.xGerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305-12. DOI: 10.1016/j.diabres.2007.05.004.Gerstein HC, Santaguida P, Raina P, Morrison KM, Balion C, Hunt D, et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305-12. DOI: 10.1016/j.diabres.2007.05.004.Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-9. DOI: 10.1016/S0140-6736(08)60766-7.Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371(9626):1783-9. DOI: 10.1016/S0140-6736(08)60766-7.Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-86. DOI: 10.1016/S0140-6736(09)61457-4. Erratum in: Lancet. 2009;374(9707):2054.Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677-86. DOI: 10.1016/S0140-6736(09)61457-4. Erratum in: Lancet. 2009;374(9707):2054.Yeboah J, Bertoni AG, Herrington DM, Post WS, Burke GL. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58(2):140-146. DOI: 10.1016/j.jacc.2011.03.025.Yeboah J, Bertoni AG, Herrington DM, Post WS, Burke GL. Impaired fasting glucose and the risk of incident diabetes mellitus and cardiovascular events in an adult population: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011;58(2):140-146. DOI: 10.1016/j.jacc.2011.03.025.Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, et al. HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011;378(9786):147-55. DOI: 10.1016/S0140-6736(11)60472-8.Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, et al. HbA1c 5·7-6·4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet. 2011;378(9786):147-55. DOI: 10.1016/S0140-6736(11)60472-8.Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010 Jul;33(7):1665-73. DOI: 10.2337/dc09-1939.Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, et al. A1C level and future risk of diabetes: a systematic review. Diabetes Care. 2010 Jul;33(7):1665-73. DOI: 10.2337/dc09-1939.Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009;58(5):1229-36. DOI: 10.2337/db08-1666.Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes. 2009;58(5):1229-36. DOI: 10.2337/db08-1666.Mihalik SJ, Michaliszyn SF, de las Heras J, Bacha F, Lee S, Chace DH, et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care. 2012;35(3):605-11. DOI: 10.2337/DC11-1577.Mihalik SJ, Michaliszyn SF, de las Heras J, Bacha F, Lee S, Chace DH, et al. Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. Diabetes Care. 2012;35(3):605-11. DOI: 10.2337/DC11-1577.Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162(4):1123-37. DOI: 10.1016/S0002-9440(10)63909-0.Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162(4):1123-37. DOI: 10.1016/S0002-9440(10)63909-0.Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820. DOI: 10.1038/414813a.Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813–820. DOI: 10.1038/414813a.Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. DOI: 10.2337/diabetes.54.6.1615.Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–1625. DOI: 10.2337/diabetes.54.6.1615.Forbes JM, Ke BX, Nguyen TV, Henstridge DC, Penfold SA, Laskowski A, et al. Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease. Antioxid Redox Signal. 2013;19(4):331-43. DOI: 10.1089/ars.2012.4719.Forbes JM, Ke BX, Nguyen TV, Henstridge DC, Penfold SA, Laskowski A, et al. Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease. Antioxid Redox Signal. 2013;19(4):331-43. DOI: 10.1089/ars.2012.4719.Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225–233. DOI: 10.2337/diabetes.55.01.06.db05-0894.Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006;55(1):225–233. DOI: 10.2337/diabetes.55.01.06.db05-0894.Wu JS, Yang YC, Lin TS, Huang YH, Chen JJ, Lu FH, et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2007;92(10):3885-9. DOI: 10.1210/jc.2006-2175.Wu JS, Yang YC, Lin TS, Huang YH, Chen JJ, Lu FH, et al. Epidemiological evidence of altered cardiac autonomic function in subjects with impaired glucose tolerance but not isolated impaired fasting glucose. J Clin Endocrinol Metab. 2007;92(10):3885-9. DOI: 10.1210/jc.2006-2175.Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008;93(7):2447-53. DOI: 10.1210/jc.2007-2174.Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008;93(7):2447-53. DOI: 10.1210/jc.2007-2174.Neves JS, Correa S, Baeta Baptista R, Bigotte Vieira M, Waikar SS, Mc Causland FR. Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. J Clin Endocrinol Metab. 2020;105(4):e1772-e1780. DOI: 10.1210/clinem/dgaa017.Neves JS, Correa S, Baeta Baptista R, Bigotte Vieira M, Waikar SS, Mc Causland FR. Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. J Clin Endocrinol Metab. 2020;105(4):e1772-e1780. DOI: 10.1210/clinem/dgaa017.Атеросклероз и дислипидемии. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. 2020;1(38):7-42. DOI: 10.34687/2219-8202.JAD.2020.01.0002.Атеросклероз и дислипидемии. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. 2020;1(38):7-42. DOI: 10.34687/2219-8202.JAD.2020.01.0002.Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Балахонова Т.В., Гуревич В.С. и др. Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА, Россия) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020). Евразийский Кардиологический Журнал. 2020;(2):6-29. DOI: 10.38109/2225-1685-2020-2-6-29.Кухарчук В.В., Ежов М.В., Сергиенко И.В., Арабидзе Г.Г., Балахонова Т.В., Гуревич В.С. и др. Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/ Национального общества по изучению атеросклероза (НОА, Россия) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020). Евразийский Кардиологический Журнал. 2020;(2):6-29. DOI: 10.38109/2225-1685-2020-2-6-29.Walther TC, Chung J, Farese RV Jr. Lipid Droplet Biogenesis. Annu Rev Cell Dev Biol. 2017;33:491-510. DOI: 10.1146/annurev-cellbio-100616-060608.Walther TC, Chung J, Farese RV Jr. Lipid Droplet Biogenesis. Annu Rev Cell Dev Biol. 2017;33:491-510. DOI: 10.1146/annurev-cellbio-100616-060608.Szeto HH, Liu S, Soong Y, Alam N, Prusky GT, Seshan SV. Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury. Kidney Int. 2016;90(5):997-1011. DOI: 10.1016/j.kint.2016.06.013.Szeto HH, Liu S, Soong Y, Alam N, Prusky GT, Seshan SV. Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury. Kidney Int. 2016;90(5):997-1011. DOI: 10.1016/j.kint.2016.06.013.Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet. 1982;2(8311):1309-11. DOI: 10.1016/s0140-6736(82)91513-6.Moorhead JF, Chan MK, El-Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet. 1982;2(8311):1309-11. DOI: 10.1016/s0140-6736(82)91513-6.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997. DOI: 10.2215/CJN.11761116. Erratum in: Clin J Am Soc Nephrol. 2017 Sep 7;12 (9):1528.Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997. DOI: 10.2215/CJN.11761116. Erratum in: Clin J Am Soc Nephrol. 2017 Sep 7;12 (9):1528.Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis. 2011;58(4):637-46. DOI: 10.1053/j.ajkd.2011.03.035.Diez-Sampedro A, Lenz O, Fornoni A. Podocytopathy in diabetes: a metabolic and endocrine disorder. Am J Kidney Dis. 2011;58(4):637-46. DOI: 10.1053/j.ajkd.2011.03.035.de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al.; ERA-EDTA Working Group Diabesity. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417-26. DOI: 10.1016/S2213-8587(14)70065-8.de Vries AP, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al.; ERA-EDTA Working Group Diabesity. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417-26. DOI: 10.1016/S2213-8587(14)70065-8.Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature. 2010;464(7290):917-21. DOI: 10.1038/nature08945.Hagberg CE, Falkevall A, Wang X, Larsson E, Huusko J, Nilsson I, et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature. 2010;464(7290):917-21. DOI: 10.1038/nature08945.Opazo-Ríos L, Mas S, Marín-Royo G, Mezzano S, Gómez-Guerrero C, Moreno JA, et al. Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities. International Journal of Molecular Sciences. 2020;21(7):2632. DOI: 10.3390/ijms21072632.Opazo-Ríos L, Mas S, Marín-Royo G, Mezzano S, Gómez-Guerrero C, Moreno JA, et al. Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities. International Journal of Molecular Sciences. 2020;21(7):2632. DOI: 10.3390/ijms21072632.Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52. DOI: 10.1016/j.kint.2016.02.026.Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52. DOI: 10.1016/j.kint.2016.02.026.Morton J, Zoungas S, Li Q, Patel AA, Chalmers J, Woodward M, et al.; ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care. 2012;35(11):2201-6. DOI: 10.2337/dc12-0306.Morton J, Zoungas S, Li Q, Patel AA, Chalmers J, Woodward M, et al.; ADVANCE Collaborative Group. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study. Diabetes Care. 2012;35(11):2201-6. DOI: 10.2337/dc12-0306.Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int. 2016;89(4):886-96. DOI: 10.1016/j.kint.2015.12.034.Bowe B, Xie Y, Xian H, Balasubramanian S, Al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney Int. 2016;89(4):886-96. DOI: 10.1016/j.kint.2015.12.034.Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, et al.; KNOW-CKD (KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators. Association Between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW-CKD. J Am Heart Assoc. 2019;8(6): e011162. DOI: 10.1161/JAHA.118.011162.Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, et al.; KNOW-CKD (KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators. Association Between Serum High-Density Lipoprotein Cholesterol Levels and Progression of Chronic Kidney Disease: Results From the KNOW-CKD. J Am Heart Assoc. 2019;8(6): e011162. DOI: 10.1161/JAHA.118.011162.Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al.; Alberta Kidney Disease Network. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24(6):979-86. DOI: 10.1681/ASN.2012080870.Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al.; Alberta Kidney Disease Network. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24(6):979-86. DOI: 10.1681/ASN.2012080870.Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018;13(3):e0192895. DOI: 10.1371/journal.pone.0192895.Major RW, Cheng MRI, Grant RA, Shantikumar S, Xu G, Oozeerally I, et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2018;13(3):e0192895. DOI: 10.1371/journal.pone.0192895.Арутюнов А. Г., Батлук Т. И., Башкинов Р. А., Трубникова М. А. Мультифокальный атеросклероз: фокус на профилактике развития ишемических событий. Российский кардиологический журнал. 2021;26(12):4808. DOI: 10.15829/1560-4071-2021-4808Арутюнов А. Г., Батлук Т. И., Башкинов Р. А., Трубникова М. А. Мультифокальный атеросклероз: фокус на профилактике развития ишемических событий. Российский кардиологический журнал. 2021;26(12):4808. DOI: 10.15829/1560-4071-2021-4808Chen C, Lü JM, Yao Q. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit. 2016;22:2501-12. DOI: 10.12659/msm.899852.Chen C, Lü JM, Yao Q. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview. Med Sci Monit. 2016;22:2501-12. DOI: 10.12659/msm.899852.Lipkowitz MS. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012;14(2):179-188. DOI: 10.1007/s11926-012-0240-z.Lipkowitz MS. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep. 2012;14(2):179-188. DOI: 10.1007/s11926-012-0240-z.Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71(6):991-999. DOI: 10.1002/art.40807.Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol. 2019;71(6):991-999. DOI: 10.1002/art.40807.Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694-700. DOI: 10.1136/annrheumdis-2011-201254.Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis. 2013;72(5):694-700. DOI: 10.1136/annrheumdis-2011-201254.Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:762820. DOI: 10.1155/2015/762820.Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. Biomed Res Int. 2015;2015:762820. DOI: 10.1155/2015/762820.Шальнова С.А., Деев А.Д., Артамонова Г.В., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014;10(1):153–159. DOI: 10.20996/1819-6446-2014-10-2-153-159.Шальнова С.А., Деев А.Д., Артамонова Г.В., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014;10(1):153–159. DOI: 10.20996/1819-6446-2014-10-2-153-159.Skoczyńska M, Chowaniec M, Szymczak A, Langner-Hetmańczuk A, Maciążek-Chyra B, Wiland P. Pathophysiology of hyperuricemia and its clinical significance - a narrative review. Reumatologia. 2020;58(5):312-323. DOI: 10.5114/reum.2020.100140.Skoczyńska M, Chowaniec M, Szymczak A, Langner-Hetmańczuk A, Maciążek-Chyra B, Wiland P. Pathophysiology of hyperuricemia and its clinical significance - a narrative review. Reumatologia. 2020;58(5):312-323. DOI: 10.5114/reum.2020.100140.Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012;8(10):610-621. DOI: 10.1038/nrrheum.2012.144.Reginato AM, Mount DB, Yang I, Choi HK. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol. 2012;8(10):610-621. DOI: 10.1038/nrrheum.2012.144.Nakagawa T, Mazzali M, Kang DH, Sánchez-Lozada LG, Herrera-Acosta J, Johnson RJ. Uric acid--a uremic toxin? Blood Purif. 2006;24(1):67-70. DOI: 10.1159/000089440.Nakagawa T, Mazzali M, Kang DH, Sánchez-Lozada LG, Herrera-Acosta J, Johnson RJ. Uric acid--a uremic toxin? Blood Purif. 2006;24(1):67-70. DOI: 10.1159/000089440.Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy. Diagnostics (Basel). 2021;11(9):1674. DOI: 10.3390/diagnostics11091674.Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy. Diagnostics (Basel). 2021;11(9):1674. DOI: 10.3390/diagnostics11091674.Kim S, Chang Y, Yun KE, Jung HS, Lee SJ, Shin H, et al. Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. Am J Kidney Dis. 2017;70(2):173-181. DOI: 10.1053/j.ajkd.2017.01.053.Kim S, Chang Y, Yun KE, Jung HS, Lee SJ, Shin H, et al. Development of Nephrolithiasis in Asymptomatic Hyperuricemia: A Cohort Study. Am J Kidney Dis. 2017;70(2):173-181. DOI: 10.1053/j.ajkd.2017.01.053.Bardin T, Nguyen QD, Tran KM, Le NH, Do MD, Richette P, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99(1):218-226. DOI: 10.1016/j.kint.2020.08.024.Bardin T, Nguyen QD, Tran KM, Le NH, Do MD, Richette P, et al. A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int. 2021;99(1):218-226. DOI: 10.1016/j.kint.2020.08.024.Sánchez-Lozada LG. The Pathophysiology of Uric Acid on Renal Diseases. Contrib Nephrol. 2018;192:17-24. DOI: 10.1159/000484274.Sánchez-Lozada LG. The Pathophysiology of Uric Acid on Renal Diseases. Contrib Nephrol. 2018;192:17-24. DOI: 10.1159/000484274.Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295(4):F1134-41. DOI: 10.1152/ajprenal.00104.2008.Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295(4):F1134-41. DOI: 10.1152/ajprenal.00104.2008.Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-6. DOI: 10.1161/hy1101.092839.Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-6. DOI: 10.1161/hy1101.092839.Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013;304(5):F471-80. DOI: 10.1152/ajprenal.00560.2012.Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013;304(5):F471-80. DOI: 10.1152/ajprenal.00560.2012.Verzola D, Ratto E, Villaggio B, Parodi EL, Pontremoli R, Garibotto G, et al. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS One. 2014;9(12):e115210. DOI: 10.1371/journal.pone.0115210.Verzola D, Ratto E, Villaggio B, Parodi EL, Pontremoli R, Garibotto G, et al. Uric acid promotes apoptosis in human proximal tubule cells by oxidative stress and the activation of NADPH oxidase NOX 4. PLoS One. 2014;9(12):e115210. DOI: 10.1371/journal.pone.0115210.Kim YJ, Oh SH, Ahn JS, Yook JM, Kim CD, Park SH, et al. The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia. Int J Mol Sci. 2020;21(20):7444. DOI: 10.3390/ijms21207444.Kim YJ, Oh SH, Ahn JS, Yook JM, Kim CD, Park SH, et al. The Crucial Role of Xanthine Oxidase in CKD Progression Associated with Hypercholesterolemia. Int J Mol Sci. 2020;21(20):7444. DOI: 10.3390/ijms21207444.Zhou F, Yu G, Wang G, Liu Y, Zhang L, Wang W, et al. Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m2 and negative proteinuria. Clin Exp Nephrol. 2019;23(7):871-879. DOI: 10.1007/s10157-019-01705-w.Zhou F, Yu G, Wang G, Liu Y, Zhang L, Wang W, et al. Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR > 60 mL/min/1.73 m2 and negative proteinuria. Clin Exp Nephrol. 2019;23(7):871-879. DOI: 10.1007/s10157-019-01705-w.Tsai CW, Lin SY, Kuo CC, Huang CC. Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. PLoS One. 2017;12(1):e0170393. DOI: 10.1371/journal.pone.0170393.Tsai CW, Lin SY, Kuo CC, Huang CC. Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. PLoS One. 2017;12(1):e0170393. DOI: 10.1371/journal.pone.0170393.Ye M, Hu K, Jin J, Wu D, Hu P, He Q. The association between time-mean serum uric acid levels and the incidence of chronic kidney disease in the general population: a retrospective study. BMC Nephrol. 2018;19(1):190. DOI: 10.1186/s12882-018-0982-6.Ye M, Hu K, Jin J, Wu D, Hu P, He Q. The association between time-mean serum uric acid levels and the incidence of chronic kidney disease in the general population: a retrospective study. BMC Nephrol. 2018;19(1):190. DOI: 10.1186/s12882-018-0982-6.Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis. 2018;71(3):362-370. DOI: 10.1053/j.ajkd.2017.08.017Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis. 2018;71(3):362-370. DOI: 10.1053/j.ajkd.2017.08.017Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407-2413. DOI: 10.1681/ASN.2008010080.Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407-2413. DOI: 10.1681/ASN.2008010080.Liu N, Wang L, Yang T, Xiong C, Xu L, Shi Y, et al. EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. J Am Soc Nephrol. 2015;26(11):2716-29. DOI: 10.1681/ASN.2014080793.Liu N, Wang L, Yang T, Xiong C, Xu L, Shi Y, et al. EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. J Am Soc Nephrol. 2015;26(11):2716-29. DOI: 10.1681/ASN.2014080793.Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-90. DOI: 10.1161/01.HYP.0000069700.62727.C5.Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-90. DOI: 10.1161/01.HYP.0000069700.62727.C5.Giordano C, Karasik O, King-Morris K, Asmar A. Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. Dis Markers. 2015;2015:382918. DOI: 10.1155/2015/382918.Giordano C, Karasik O, King-Morris K, Asmar A. Uric Acid as a Marker of Kidney Disease: Review of the Current Literature. Dis Markers. 2015;2015:382918. DOI: 10.1155/2015/382918.Xia X, Luo Q, Li B, Lin Z, Yu X, Huang F. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2016;65(9):1326-1341. DOI: 10.1016/j.metabol.2016.05.009.Xia X, Luo Q, Li B, Lin Z, Yu X, Huang F. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2016;65(9):1326-1341. DOI: 10.1016/j.metabol.2016.05.009.Tsai CW, Chiu HT, Huang HC, Ting IW, Yeh HC, Kuo CC. Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses. Nephrol Dial Transplant. 2018;33(2):231-241. DOI: 10.1093/ndt/gfx297.Tsai CW, Chiu HT, Huang HC, Ting IW, Yeh HC, Kuo CC. Uric acid predicts adverse outcomes in chronic kidney disease: a novel insight from trajectory analyses. Nephrol Dial Transplant. 2018;33(2):231-241. DOI: 10.1093/ndt/gfx297.Sharma G, Dubey A, Nolkha N, Singh JA. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211016661. DOI: 10.1177/1759720X211016661.Sharma G, Dubey A, Nolkha N, Singh JA. Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211016661. DOI: 10.1177/1759720X211016661.Мазуров В.И., Гайдукова И.З., Башкинов Р.А., Фонтуренко А.Ю., Петрова М.С., Инамова О.В. Влияние бессимптомной гиперурикемии на течение коморбидной патологии у пациентов с остеоартритом и возможности ее коррекции. РМЖ. 2021;29(6):56-62. eLIBRARY ID: 46433904Мазуров В.И., Гайдукова И.З., Башкинов Р.А., Фонтуренко А.Ю., Петрова М.С., Инамова О.В. Влияние бессимптомной гиперурикемии на течение коморбидной патологии у пациентов с остеоартритом и возможности ее коррекции. РМЖ. 2021;29(6):56-62. eLIBRARY ID: 46433904Luo Q, Xia X, Li B, Lin Z, Yu X, Huang F. Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2019;20(1):18. DOI: 10.1186/s12882-018-1143-7.80 Luo Q, Xia X, Li B, Lin Z, Yu X, Huang F. Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 2019;20(1):18. DOI: 10.1186/s12882-018-1143-7.Wu N, Xia J, Chen S, Yu C, Xu Y, Xu C, et al. Serum uric acid and risk of incident chronic kidney disease: a national cohort study and updated meta-analysis. Nutr Metab (Lond). 2021;18(1):94. DOI: 10.1186/s12986-021-00618-4.Wu N, Xia J, Chen S, Yu C, Xu Y, Xu C, et al. Serum uric acid and risk of incident chronic kidney disease: a national cohort study and updated meta-analysis. Nutr Metab (Lond). 2021;18(1):94. DOI: 10.1186/s12986-021-00618-4.Xu X, Hu J, Song N, Chen R, Zhang T, Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):27. DOI: 10.1186/s12882-016-0433-1.Xu X, Hu J, Song N, Chen R, Zhang T, Ding X. Hyperuricemia increases the risk of acute kidney injury: a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):27. DOI: 10.1186/s12882-016-0433-1.Yang H, Chen Q, Huang A, Yu X, Chen G, Hu X, et al.The Impact of hyperuricemia on long-term clinical outcomes of renal transplant recipients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:292-307. DOI: 10.18433/jpps31620.Yang H, Chen Q, Huang A, Yu X, Chen G, Hu X, et al.The Impact of hyperuricemia on long-term clinical outcomes of renal transplant recipients: a systematic review and meta-analysis. J Pharm Pharm Sci. 2021;24:292-307. DOI: 10.18433/jpps31620.Zhang K, Tang L, Jiang SS, Wang YF, Meng Y, Wang MD, et al. Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies. Ren Fail. 2022;44(1):70-80. DOI: 10.1080/0886022X.2021.2019589.Zhang K, Tang L, Jiang SS, Wang YF, Meng Y, Wang MD, et al. Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies. Ren Fail. 2022;44(1):70-80. DOI: 10.1080/0886022X.2021.2019589.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. DOI: 10.1016/S0140-6736(17)32129-3.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627-2642. DOI: 10.1016/S0140-6736(17)32129-3.Obesity: missing the 2025 global targets. Trends, Costs and Country Reports. World Obesity Federation. London, 2020.Obesity: missing the 2025 global targets. Trends, Costs and Country Reports. World Obesity Federation. London, 2020.Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008 Dec;29(24):2959-71. DOI: 10.1093/eurheartj/ehn387.Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008 Dec;29(24):2959-71. DOI: 10.1093/eurheartj/ehn387.Аметов А.С., Цыганкова О.В. Комплексная метаболическая протекция как современная стратегия управления сахарным диабетом 2 типа. Эндокринология: новости, мнения, обучение. 2021;10(2):93–104. DOI: 10.33029/2304-9529-2021-10-2-93-104.Аметов А.С., Цыганкова О.В. Комплексная метаболическая протекция как современная стратегия управления сахарным диабетом 2 типа. Эндокринология: новости, мнения, обучение. 2021;10(2):93–104. DOI: 10.33029/2304-9529-2021-10-2-93-104.Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76(2):145-8. DOI: 10.1038/ki.2009.137.Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76(2):145-8. DOI: 10.1038/ki.2009.137.Ellington AA, Malik AR, Klee GG, Turner ST, Rule AD, Mosley TH Jr, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50(4):708-14. DOI: 10.1161/HYPERTENSIONAHA.107.095257.Ellington AA, Malik AR, Klee GG, Turner ST, Rule AD, Mosley TH Jr, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007;50(4):708-14. DOI: 10.1161/HYPERTENSIONAHA.107.095257.Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006;151:175-183. DOI: 10.1159/000095328.Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006;151:175-183. DOI: 10.1159/000095328.Kopple JD, Feroze U. The effect of obesity on chronic kidney disease. J Ren Nutr. 2011;21(1):66-71. DOI: 10.1053/j.jrn.2010.10.009.Kopple JD, Feroze U. The effect of obesity on chronic kidney disease. J Ren Nutr. 2011;21(1):66-71. DOI: 10.1053/j.jrn.2010.10.009.Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant. 2005;20(12):2594-7. DOI: 10.1093/ndt/gfi201.Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant. 2005;20(12):2594-7. DOI: 10.1093/ndt/gfi201.Weinberg J.M. Lipotoxicity. Kidney Int. 2006 Nov;70(9):1560-6. DOI: 10.1038/sj.ki.5001834.Weinberg J.M. Lipotoxicity. Kidney Int. 2006 Nov;70(9):1560-6. DOI: 10.1038/sj.ki.5001834.Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int. 2015;87(6):1216-22. DOI: 10.1038/ki.2014.384.Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int. 2015;87(6):1216-22. DOI: 10.1038/ki.2014.384.Cao X, Zhou J, Yuan H, Wu L, Chen Z. Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort. BMC Nephrol. 2015;16:85. DOI: 10.1186/s12882-015-0083-8.Cao X, Zhou J, Yuan H, Wu L, Chen Z. Chronic kidney disease among overweight and obesity with and without metabolic syndrome in an urban Chinese cohort. BMC Nephrol. 2015;16:85. DOI: 10.1186/s12882-015-0083-8.Chang A, Van Horn L, Jacobs DR Jr, Liu K, Muntner P, Newsome B, et al. Lifestyle-related factors, obesity, and incident microalbuminuria: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Kidney Dis. 2013;62(2):267-75. DOI: 10.1053/j.ajkd.2013.02.363.Chang A, Van Horn L, Jacobs DR Jr, Liu K, Muntner P, Newsome B, et al. Lifestyle-related factors, obesity, and incident microalbuminuria: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Kidney Dis. 2013;62(2):267-75. DOI: 10.1053/j.ajkd.2013.02.363.Herrington WG, Smith M, Bankhead C, Matsushita K, Stevens S, Holt T, et al. Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England. PLoS One. 2017;12(3):e0173515. DOI: 10.1371/journal.pone.0173515.Herrington WG, Smith M, Bankhead C, Matsushita K, Stevens S, Holt T, et al. Body-mass index and risk of advanced chronic kidney disease: Prospective analyses from a primary care cohort of 1.4 million adults in England. PLoS One. 2017;12(3):e0173515. DOI: 10.1371/journal.pone.0173515.Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19-33. DOI: 10.1038/sj.ki.5002586.Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19-33. DOI: 10.1038/sj.ki.5002586.Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224-1235. DOI: 10.1016/j.kint.2016.12.013.Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224-1235. DOI: 10.1016/j.kint.2016.12.013.Zhang J, Jiang H, Chen J. Combined effect of body mass index and metabolic status on the risk of prevalent and incident chronic kidney disease: a systematic review and meta-analysis. Oncotarget. 2017;8(22):35619-35629. DOI: 10.18632/oncotarget.10915.Zhang J, Jiang H, Chen J. Combined effect of body mass index and metabolic status on the risk of prevalent and incident chronic kidney disease: a systematic review and meta-analysis. Oncotarget. 2017;8(22):35619-35629. DOI: 10.18632/oncotarget.10915.Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, et al. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015;10(4):578-83. DOI: 10.2215/CJN.08980914.Hashimoto Y, Tanaka M, Okada H, Senmaru T, Hamaguchi M, Asano M, et al. Metabolically healthy obesity and risk of incident CKD. Clin J Am Soc Nephrol. 2015;10(4):578-83. DOI: 10.2215/CJN.08980914.Jung CH, Lee MJ, Kang YM, Hwang JY, Kim EH, Park JY, et al. The risk of chronic kidney disease in a metabolically healthy obese population. Kidney Int. 2015;88(4):843-50. DOI: 10.1038/ki.2015.183.Jung CH, Lee MJ, Kang YM, Hwang JY, Kim EH, Park JY, et al. The risk of chronic kidney disease in a metabolically healthy obese population. Kidney Int. 2015;88(4):843-50. DOI: 10.1038/ki.2015.183.Lin L, Peng K, Du R, Huang X, Lu J, Xu Y, et al. Metabolically healthy obesity and incident chronic kidney disease: The role of systemic inflammation in a prospective study. Obesity (Silver Spring). 2017;25(3):634-641. DOI: 10.1002/oby.21768.Lin L, Peng K, Du R, Huang X, Lu J, Xu Y, et al. Metabolically healthy obesity and incident chronic kidney disease: The role of systemic inflammation in a prospective study. Obesity (Silver Spring). 2017;25(3):634-641. DOI: 10.1002/oby.21768.Nam KH, Yun HR, Joo YS, Kim J, Lee S, Lee C, et al. Changes in obese metabolic phenotypes over time and risk of incident chronic kidney disease. Diabetes Obes Metab. 2018;20(12):2778-2791. DOI: 10.1111/dom.13458.Nam KH, Yun HR, Joo YS, Kim J, Lee S, Lee C, et al. Changes in obese metabolic phenotypes over time and risk of incident chronic kidney disease. Diabetes Obes Metab. 2018;20(12):2778-2791. DOI: 10.1111/dom.13458.Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36-46. DOI: 10.1016/S1470-2045(14)71123-4.Arnold M, Pandeya N, Byrnes G, Renehan PAG, Stevens GA, Ezzati PM, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36-46. DOI: 10.1016/S1470-2045(14)71123-4.Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 20086;371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X.Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 20086;371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X.Pinto KRD, Feckinghaus CM, Hirakata VN. Obesity as a predictive factor for chronic kidney disease in adults: systematic review and meta-analysis. Braz J Med Biol Res. 2021;54(4):e10022. DOI: 10.1590/1414-431X202010022.Pinto KRD, Feckinghaus CM, Hirakata VN. Obesity as a predictive factor for chronic kidney disease in adults: systematic review and meta-analysis. Braz J Med Biol Res. 2021;54(4):e10022. DOI: 10.1590/1414-431X202010022.Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, Gillen D, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis. 2014;56(4):415-25. DOI: 10.1016/j.pcad.2013.10.005.Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, Gillen D, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis. 2014;56(4):415-25. DOI: 10.1016/j.pcad.2013.10.005.

The authors declare that there are no conflicts of interest present.